Fresenius Medical Care stock trades at USD 22.54 below yearly high

Published on 09/25/2026 at 16:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius Medical Care stock delivered Q2 operating income of EUR 569 million on August 3, 2026, up 23 percent at constant currency. Analysts see USD 23.57 on average.

Moderner Dialyseraum mit Hämodialysegeräten und Patientenliegen bei Tageslicht — Ein fotorealistisches Bild eines modernen Dialyseraums mit mehreren Hämodialysegeräten und Patientenliegen in Reihe, ruhigem Tageslicht durch große Fenster – typisch für die Behandlungszentren von Fresenius Medical Care AG (ISIN DE0005785802), Illustration mit AI erstellt.

Fresenius Medical Care (DE0005785802) was trading at USD 22.54 on the NYSE on September 25, 2026, at 10:39 a.m. ET, up 0.83 percent from USD 22.35. The stock remains 18.45 percent below its 52-week high of USD 27.64, making the latest quarterly profitability update more important than the modest daily move.

Q2 operating income rises 23 percent

According to Fresenius Medical Care in its investor update, the company reported second-quarter 2026 results on August 3, 2026. Operating income increased 23 percent, while the underlying operating result improved 34 percent after adjustment for positive TDAPA effects.

The company also confirmed its 2026 outlook. The operational improvement was supported by higher reimbursement rates and positive revenue cycle management effects, according to the same investor update from Fresenius Medical Care.

Revenue reaches EUR 4.861 billion

The Globe and Mail reported that second-quarter revenue rose 4 percent at constant currency to EUR 4,861 million. Operating income excluding special items reached EUR 569 million, and the result exceeded market expectations.

Fresenius Medical Care is expanding its 5008X CAREsystem in the United States. The technology was available in 227 US clinics and had been used in more than 600,000 treatments by the Q2 update, giving the profitability figures an operating foothold in the companys core market.

Analyst target stays above the price

MarketBeat reported on September 25, 2026, that 11 rating firms assigned Fresenius Medical Care a consensus recommendation of Reduce and an average 1-year target of USD 23.57. The target lies 4.57 percent above the NYSE price of USD 22.54.

The next quarterly results are scheduled for November 3, 2026, according to Fresenius Medical Care. For investors, the key test is whether the Q2 operating improvement can continue while US treatment volumes and the companys confirmed full-year outlook remain central to the valuation.

Stock stays below its yearly high

Fresenius Medical Care stock had a market capitalization of USD 12,104,208,257 and volume of 67,759 shares on September 25, 2026. Its 52-week range was USD 20.02 to USD 27.64, placing the intraday price closer to the yearly low than the high.